Companies in #Fibrosis

aTyr Pharma is a clinical-stage biotechnology company in San Diego that builds therapies from tRNA synthetase biology, a family of naturally occurring proteins whose extracellular domains regulate inflammation, fibrosis and immune signalling. Its lead candidate efzofitimod is a selective modulator of neuropilin-2 (NRP-2) developed for pulmonary sarcoidosis and other interstitial lung diseases. The Phase 3 EFZO-FIT trial in 268 patients missed its primary endpoint of reducing oral corticosteroid dose at week 48, a result announced in September 2025 and published in The Lancet Respiratory Medicine in October 2026, though the 5.0 mg/kg arm showed benefits on patient-reported outcomes and maintained forced vital capacity. The company continues a Phase 2 study in systemic sclerosis-associated interstitial lung disease and has begun start-up activities for a further global Phase 3, alongside preclinical programmes ATYR0101 for fibrosis, ATYR0750 for liver disorders and the anti-NRP2 antibody ATYR2810 in oncology. aTyr has a collaboration with Kyorin Pharmaceutical for efzofitimod in Japan and executed a 1-for-40 reverse stock split in October 2026 to address the Nasdaq minimum bid price requirement, reducing shares outstanding from roughly 100.5 million to about 2.5 million.

Enveda is an AI-driven drug discovery company that reads nature's untapped chemistry through metabolomics and machine learning to discover small-molecule medicines roughly four times faster than the industry average. Its pipeline spans obesity and metabolic disease, immunology and inflammation, fibrosis and neurosensory disorders, and the company has raised more than $845 million since 2019.

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

PureTech Health is a clinical-stage biotherapeutics company developing innovative medicines for serious diseases. It founded and spun out multiple companies including Karuna, Gelesis, and Celea, with a current focus on lymphatic and CNS-targeted therapeutics.

Redx Pharma is a clinical-stage biopharmaceutical company developing precision medicines targeting oncology and fibrotic diseases, with a pipeline of small molecule inhibitors of oncogenic and fibrotic pathways.

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead product, apitegromab, is being developed for spinal muscular atrophy (SMA).

Clinical-stage biopharmaceutical company developing peripheral CB1 receptor therapies for obesity and metabolic conditions. Recently combined with Redx Pharma into Fibrx Therapeutics to advance a fibrosis-focused pipeline.